The anti-tumor effect of CD27 ligation has been shown in different cancers, for example, the agonist Anti-CD27 Antibodies, i.e., the antibodies that activate CD27 rather than block its activity (like antagonistic antibodies), demonstrated the anti-tumor efficacy in both animal models42,43 and human phase I trials44. Here, CD27 is linked to neoplasm.